CG Oncology, Inc.

Biological Products, (No Diagnostic Substances)·DALLAS, TX·FY end 12/31·CIK 1991792

Overview Financials Compensation Governance Insiders Filings

Named Executive Officers

FY 2025

Executive	Salary	Stock	Options	Bonus / Inc.	Other	Total
Arthur KuanChief Executive Officer	$690.0K	$3.5M	$7.4M	$414.0K	$22.0K	$11.9M
Ambaw BelletePresident and Chief Operating Officer	$537.9K	—	$4.0M	$269.0K	$40.9K	$4.8M
Vijay KasturiChief Medical Officer	$502.9K	—	$2.8M	$226.3K	$30.7K	$3.6M
Joshua F. PattersonGeneral Counsel, Chief Compliance Officer, and Secretary	$461.5K	—	$1.7M	$207.7K	$24.6K	$2.4M
Corleen RochePrior Chief Financial Officer	$288.9K	—	$2.0M	—	$28.7K	$2.3M
Robert Lapetina (PriorInterim Principal Financial and Accounting Officer)	$310.2K	—	$300.7K	$2.3K	$32.1K	$645.3K
Jim DeToreChief Financial Officer	$96.0K	—	—	—	—	$96.0K

CEO pay mix

Arthur Kuan · FY 2025

Stock awards$3.5M29%

Performance bonus$414.0K3%

Salary$690.0K6%

Other$7.4M62%

Performance vs. pay

Item 402(v) Pay-Versus-Performance disclosure data not yet ingested for this company. Mandatory only for FYs ending on/after Dec 16, 2022 — older companies may not have filed it yet.

CEO comp · median worker · ratio — multi-year trend

Need at least two fiscal years of proxy data to draw the trend line. The ingestion worker will populate prior-year proxies as it processes them.